바로가기 메뉴

단축키 목록

맨 위로

현재 페이지 위치 : 삼성유전체연구소 > PLATFORM > LiquidSCAN™

LiquidSCAN™

 

Actionable genome analysis solutions

LiquidSCAN™

Tissue biopsies to monitor genetic alterations in primary tumors and metastases are often difficult for practical reasons, and thus minimally invasive methods have been highly anticipated.

The level of circulating tumor DNA (ctDNA) has been demonstrated to correlate with tumor burden over time; this implicated its potential application in monitoring tumor progression, therapeutic response, and drug resistance.

Highly sensitive methods detecting ctDNA might be valuable for developing screening tests to identify cancers at their early stages either in high-risk groups or even in healthy population.

Compared to conventional PCR, targeted deep sequencing enables broader coverage of a target to detect somatic mutations in cell-free DNA (cfDNA).

We optimized a NGS protocol that is critical for creating a high complexity library using a limited amount of input cfDNA. Systematic characterization of background errors in sequencing data aids in achieving high specificity by discriminating true cancer-related variants from artifactual mutations. Our high coverage NGS method allows identification of tumor-specific somatic mutations with a high sensitivity and specificity.

 

 · Contact

    Donghyun Park, PhD

    Senior Staff Scientist

    T +82-2-2148-2954

    E-mail dh37.park@samsung.com